A very small group of patients consume a significant portion of outpatient primary care physician time.
Infliximab, an antibody against tumor necrosis factor, is effective in ulcerative colitis.
A new drug has been approved for the treatment of children with below average height who are resistant to growth hormone. Mecasermin is a human insulin-like growth factor-1 (IGF-1) that is produced by recombinant DNA technology. This protein is marketed by Tercica, Incorporated as Increlex.
FDA Recommends Approval of Muraglitazar, But May Need To Reconsider; Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions
A program of resistive exercise and treadmill walking reduced the severity of restless legs syndrome symptoms.
People who have symptoms of allergic rhinitis report more sleep complaints, including daytime sleepiness, than do those without allergic rhinitis.
The FDA has approved a new antifungal agent for the prevention of Aspergillus and Candida infections in at-risk individuals. Posaconazole is an oral triazole, broad spectrum, antifungal chemically similar to itraconazole.
In the United States, COPD is the 4th leading cause of death. Widespread public education about smoking toxicity has not decreased COPD mortality, and since 2000 the number of women who die from COPD has eclipsed men.
